This blend consists of two peptides that seem to share the potential to boost the growth hormone axis, using various mechanisms. It is believed that Tesamorelin and Ipamorelin blend synergistically to activate the pituitary gland, which results in the release of endogenous growth hormone.
In laboratory settings, scientists discovered that this blend may offer potential means to optimize growth hormone levels that could positively affect lipid profile, lean mass, muscle tissue, cognition, metabolic function, and sleep.
Tesamorelin, Ipamorelin 10mg research
Growth hormone deficiency
While this blend tends to exert its potential through distinct mechanisms of action, they complement each other. Tesamorelin, a GHRH or growth hormone-releasing hormone analog, appears to act by binding to and activating the GHRH receptor on somatotrophs in the pituitary gland.
This stimulation may induce the secretion and synthesis of growth hormone (GH) in a pulsatile pattern. According to a study conducted on rats, scientists found that Tesamorelin may improve glucose metabolism, minimize visceral adipose tissue, and boost lipolysis.
On the other hand, Ipamorelin seems to activate GHSR in peripheral tissues and the hypothalamus, leading to the release of GH. Ipamorelin appears to exhibit a high selectivity for GHSR, without interfering with other hormones.
When they are combined, Tesamorelin and Ipamorelin may offer a synergetic impact because they target different components of the GH axis. Tesamorelin has been known to boost GHRH-mediated GH release, while Ipamorelin could directly stimulate GHSR to increase GH secretion. In laboratory settings, this dual action could enhance the overall GH, like improved metabolic function, insulin sensitivity, lipid profile, and better body composition.
Pituitary Gland
According to numerous research, Tesamorelin seems to affect the pituitary gland, a crucial organ considered to be responsible for GH secretion. Studies indicate that Tesamorelin may target GHRHR or growth hormone–releasing hormone receptors that lead to subsequent release.
It seems that this peptide may potentially increase total growth hormone by 69% and, allegedly, a 55% increase in the mean pulse area of the GH.
Studies indicate that Ipamorelin may act as a potent agonist for GHRS and promote GH secretion. In research, Ipamorelin exhibited the potential to enhance GH levels, reaching levels up to 80mlU/I.
When these peptides are combined, they seem to have synergetic action on the pituitary gland, which may lead to higher GH production.
Lipodystrophy
Clinical trials suggest that an increased risk of cardiovascular complications, dyslipidemia, and insulin resistance often accompanies lipodystrophy. Research has shown that Tesamorelin found in lipodystrophic tissue might reduce VAT or visceral adipose tissue and improve lipid profiles and insulin sensitivity.
This peptide seems to activate GHRHR and potentially promote lipolysis, stimulate endogenous growth hormone secretion, improve body image and lipids, and preserve abdominal subcutaneous adipose tissue. At the same time, Ipamorelin has been reported to have a similar effect and the ability to influence adipose tissue metabolism. However, by combining these two peptides, scientists suggest they can reduce VAT and improve metabolic parameters concerning lipodystrophy test models.
Type 2 diabetes
Emerging evidence from both preclinical and clinical studies in the literature has focused attention on the potential of Tesamorelin and Ipamorelin in addressing glycemic irregularities and metabolic dysfunction associated with T2DM.
Tesamorelin has been noted to increase endogenous growth hormone secretion levels, a mechanism by which scientists associate improved insulin sensitivity and enhanced glucose metabolism.
Studies on Ipamorelin indicate that this peptide may also have beneficial effects on glucose control and insulin sensitivity. In combination, Tesamorelin and Ipamorelin might act synergistically to achieve decreases in HbA1c, enhanced insulin sensitivity, and reduced visceral adiposity in individuals with T2DM.
Cognitive Enhancement
Preclinical data shows promising findings when it comes to Tesamorelin and memory capacity and learning. In particular, the administration of Ipamorelin has also shown capabilities that result in increased spatial memories with consequent cognitive performances in various tested animals.
Together, these peptides could potentially further enhance cognition through complementary modes of action that involve the stimulation of the growth hormone axis and neurotrophic factors, which makes this topic particularly interesting in terms of cognitive health.
Muscle Density
Research of the effects of Tesamorelin on muscle tissue integrity, as measured by computed tomography scans, shows potential increases in muscle density and size. Muscle groups, such as the rectus abdominis, psoas major, and paraspinal muscles, had significant changes in either increased density, size, or reduced fat content. These changes were statistically significant compared with placebo, but changes in IGF-1 levels did not directly relate to changes in muscle structure.
Similarly, experimental studies indicate that Ipamorelin could exert similar action as Tesamorelin in enhancing skeletal muscle size and strength. Initial results indicate that Ipamorelin may interact with IGF-1 in ways that increase the cross-sectional area of muscle fiber volume. These findings, obtained in murine experiments, indicate that Ipamorelin may enhance muscular performance and integrity.
Bone Health
Ipamorelin has also shown promise in supporting bone health, with some evidence that it may stimulate the activity of bone formation and improve bone mass. Animal research indicates a possible increase in bone mineral content, which may be linked to Ipamorelin’s action. In one study, Ipamorelin-treated animals gained weight and BMC, but when body weight changes were taken into account, the BMC-to-body-weight ratio remained unchanged.
In vitro analyses further suggest that cortical bone growth may contribute to elevated BMC, while volumetric bone mineral density (vBMD) remained stable. These findings highlight the peptide’s potential to enhance bone area without compromising bone density. This might reflect the synergistic potential of Tesamorelin and Ipamorelin for bone health in an additive manner, complementing each other’s mechanisms. Further studies are warranted to confirm these changes and their chronic implication for skeletal health.
References:
- Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. doi: 10.14283/jfa.2018.45. PMID: 31237318; PMCID: PMC6766405.
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014 Dec;29(12):1527-34. doi: 10.1007/s00384-014-2030-8. Epub 2014 Oct 21. PMID: 25331030.
- Fourman LT, Czerwonka N, Feldpausch MN, Weiss J, Mamputu JC, Falutz J, Morin J, Marsolais C, Stanley TL, Grinspoon SK. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017 Oct 23;31(16):2253-2259. doi: 10.1097/QAD.0000000000001614. PMID: 28832410; PMCID: PMC5633509.
-
Michael Ankersen, Nils L. Johansen, Kjeld Madsen, Birgit S. Hansen, Kirsten Raun, Karin Kramer Nielsen, Henning Thøgersen, Thomas K. Hansen, Bernd Peschke, Jesper Lau, Behrend F. Lundt, and Peter H. Andersen Journal of Medicinal Chemistry 1998 41 (19), 3699-3704
Our support team is at your service, ensuring customer satisfaction.
